Hyperpigmentation

Hempz Kicks Off 2024 with Expansion of Beauty Actives Collection and Launch of New Herbal Body Oils

Retrieved on: 
Thursday, February 1, 2024
Honey, Melon, Mineral, Vitamin, Hyperpigmentation, Vanilla, Aloe, Tea tree oil, Mint, Collection, Hyaluronic acid, Skin, Vitamin C, Jojoba, Retinol, Lavandula, Cosmetics

The breakthrough collection features Ocean Breeze Herbal Body Moisturizer with Hyaluronic Acid, Citrus Blossom Herbal Body Moisturizer with Brightening Vitamin C, Sweet Jasmine & Rose Herbal Body Moisturizer with Vegan Collagen, Cucumber & Aloe Herbal Body Moisturizer formulated with Ceramides + B3, and Lavender & Chamomile Herbal Body Moisturizer with Bakuchiol (Retinol Alternative).

Key Points: 
  • The breakthrough collection features Ocean Breeze Herbal Body Moisturizer with Hyaluronic Acid, Citrus Blossom Herbal Body Moisturizer with Brightening Vitamin C, Sweet Jasmine & Rose Herbal Body Moisturizer with Vegan Collagen, Cucumber & Aloe Herbal Body Moisturizer formulated with Ceramides + B3, and Lavender & Chamomile Herbal Body Moisturizer with Bakuchiol (Retinol Alternative).
  • This year, Hempz is thrilled to introduce two new additions to the collection - Beauty Actives Vanilla Lux Herbal Body Moisturizer with Niacinamide and Beauty Actives Tea Tree Herbal Body Moisturizer with Tea Tree Oil.
  • Hempz Beauty Actives Vanilla Lux Herbal Body Moisturizer with Niacinamide harnesses the power of niacinamide to promote anti-aging and improve the appearance of pores, skin texture, hyperpigmentation.
  • Hempz Original Herbal Body Oil, Hempz Sweet Pineapple & Honey Melon Herbal Body Oil, and Hempz Triple Moisture Fresh Citrus Herbal Body Oil have a suggested retail price of $12.99 and can be purchased online at Hempz.com or Ulta.com.

Global Cosmetics Analysis Report 2023: Market to Reach $523.5 Billion by 2028 - Trends, Share, Size, Growth, Opportunities and Forecasts - Demand for Ethical Products Rises, E-commerce Platforms Surge - ResearchAndMarkets.com

Retrieved on: 
Monday, January 15, 2024
Cosmetics, Retail, Woman, UV, Supermarket, Social media, Health, Dry, Radiation, Advertising, Sport, Environment, Hyperpigmentation, Skin, Consumer, Travel, Urbanization, Internet celebrity, Acne, Ageing

Looking forward, the market is expected to reach US$ 523.5 Billion by 2028, exhibiting a growth rate (CAGR) of 5.50% during 2022-2028.

Key Points: 
  • Looking forward, the market is expected to reach US$ 523.5 Billion by 2028, exhibiting a growth rate (CAGR) of 5.50% during 2022-2028.
  • The market is primarily driven by the rising beauty consciousness among individuals, and the growing preference for customized cosmetic products.
  • Social media platforms provide a space for consumers to discover, discuss, and share experiences about cosmetics products, influencing purchasing decisions and fueling market growth.
  • As consumers seek to maintain a youthful appearance and address specific skincare concerns, there is a growing demand for anti-aging products.

Global Microdermabrasion Devices Market Report 2023: A $496 Million Industry in 2022 - Industry Trends, Share, Size, Growth, Opportunity and Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024
Cosmetics, Retail, Health, Consumer, Other Retail, Women, Other Health, Hospital, Melasma, Aluminium, John Foster Dulles, Hyperpigmentation, Skin, COVID-19, Smash Mouth, Vacuum, Collagen, Acne, Ageing, Suction, Prevalence

The "Global Microdermabrasion Devices Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Microdermabrasion Devices Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global microdermabrasion devices market size reached US$ 496.1 Million in 2022.
  • Microdermabrasion devices are mechanical exfoliation equipment used for improving the texture of the skin and reducing the appearance of superficial blemishes.
  • What is the structure of the global microdermabrasion devices market and who are the key players?

New Year, New Skincare Goals

Retrieved on: 
Thursday, January 4, 2024
Peel (fruit), Smash Mouth, Injectable filler, Dermatology, Sun protection, Hyperpigmentation, Treatment, Multimedia, Vegetable, Serum, Mediterranean diet, Elastin, Friends, Absorption, Diet, Skin, Paralysis, Filler (linguistics), Seal, AOX, GamePro, Collagen, MD, Collagen induction therapy, Peel, Skin care, Human, Water, Antioxidant, Ageing, Acne, SPF, Day spa, Lunch, Enzyme, Diet (assembly), Moisturizer, Rodan + Fields, Skin Cancer Foundation, Reader's Digest, Digest, Cosmetics

The combination of ZO® Daily Power Defense and ZO® Illuminating AOX Serum is a staple in my clients' skincare regimens.

Key Points: 
  • The combination of ZO® Daily Power Defense and ZO® Illuminating AOX Serum is a staple in my clients' skincare regimens.
  • Here are some key benefits of incorporating medical-grade skincare into your routine:
    Higher Concentrations of Active Ingredients: Medical-grade skincare products often contain higher concentrations of active ingredients compared to over-the-counter products.
  • Professional Guidance: Medical-grade skincare products are typically recommended or prescribed by skincare professionals, such as dermatologists or aestheticians.
  • At Nash Injections by Hannah, we firmly believe in empowering you to make well-informed decisions regarding your skincare treatments.

Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640

Retrieved on: 
Thursday, January 4, 2024
Blood pressure, MC4R, Bardet–Biedl syndrome, Food, Hyperpigmentation, Body mass index, Heart rate, Polyphagia, Chemistry, Chair, Weight loss, POMC, LG Chem, SIGNAL, MD, Pharmacokinetics, Obesity, PCSK1, Patient, Safety, BBS, LEPR, Pharmaceutical industry

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced it has entered into a global licensing agreement with LG Chem, Ltd. ("LG Chem"), a leading global company headquartered in South Korea that specializes in life sciences as one of its core businesses, for LB54640, an investigational oral small molecule melanocortin-4 receptor (MC4R) agonist now in Phase 2 clinical trials.

Key Points: 
  • “We are excited to build upon the strong chemistry and early translational work performed by LG Chem, a highly regarded company with deep and broad experience and expertise in the pharmaceutical business.
  • LB54640 also demonstrated a favorable safety profile in the trial, with no changes in blood pressure or heart rate observed and no hyperpigmentation observed.
  • In addition, LB54640 has received orphan drug designation from the U.S. Food and Drug Administration for leptin receptor (LEPR) deficiency and proopiomelanocortin(POMC).
  • Also under the terms of the agreement, Rhythm has agreed to pay LG Chem up to $205 million upon achieving certain regulatory and sales milestones, as well as royalties.

Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates

Retrieved on: 
Thursday, January 4, 2024
Bardet–Biedl syndrome, Hyperpigmentation, Medicine, Deficit spending, IND, Polyphagia, FDA, Polydactyly, Prevalence, POMC, International, Visual impairment, Syndrome, Investigational New Drug, Ministry, Obesity, PCSK1, Patient, Hunger, Hypogonadism, BBS, LEPR, Pharmaceutical industry

BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today provided a business update and announced it has completed screening for enrollment in the pivotal, Phase 3 clinical trial evaluating setmelanotide in patients with acquired hypothalamic obesity.

Key Points: 
  • Rhythm closed screening and anticipates overenrolling the ongoing phase 3 hypothalamic obesity trial with more than 140 patients consented and going through active screening and baseline assessments.
  • In this trial, patients with acquired hypothalamic obesity aged 4 years or older will be randomized 2:1 to setmelanotide therapy or placebo for a total of 60 weeks, including up to eight weeks for dose titration.
  • Rhythm estimates the prevalence of BBS to be approximately 700 people in Spain with approximately 100 patients identified.
  • The Company anticipates beginning Phase 1 in-human trials in the first half of 2024, including a multiple-ascending dose study in patients with hypothalamic obesity.

Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event

Retrieved on: 
Wednesday, December 6, 2023
Bardet–Biedl syndrome, Quality of life, Genotype, Food, Stage 2, Hyperpigmentation, Life, Shanda, Polyphagia, FDA, Type, Weight loss, POMC, BMI, European, Disease, MC1R, University of Florida, MD, Pediatric endocrinology, New Drug Application, University, SIM1, Obesity, TBX3, Endocrinology, PCSK1, Human, Patient, Proopiomelanocortin, Hunger, BBS, LEPR, Pharmaceutical industry

-- Company to host R&D webcast today at 8:00 a.m. ET--

Key Points: 
  • “Today, we are excited to showcase our commitment to understanding the MC4R pathway and developing the next generation of therapies,” said David Meeker, M.D., Chair, President and Chief Executive Officer of Rhythm.
  • The hyperphagia and severe obesity of rare genetically-caused MC4R pathway diseases can present early in life, and these data show potential efficacy in patients younger than 6.
  • A live webcast of the R&D call will be available under "Events and Presentations" in the Investor Relations section of the Rhythm Pharmaceuticals website at https://ir.rhythmtx.com/ .
  • The archived webcast will be available on Rhythm Pharmaceuticals’ website approximately two hours after the conference call and will be available for 30 days following the call.

Codex Labs Announces the SGBNET Portal for Genetic Counselling and DECODE DNA Tests for Skin Conditions and Vitamin Deficiencies

Retrieved on: 
Friday, December 1, 2023
Hyperpigmentation, Dermatology, Metabolism, Vitamin, Real-time, Absorption, Diet, Comedo, Mental health, Acne, Silicon

San Jose, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Codex Labs, Silicon Valley’s biotech skintech company announced the launch of its SGBNET platform.

Key Points: 
  • San Jose, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Codex Labs, Silicon Valley’s biotech skintech company announced the launch of its SGBNET platform.
  • The platform includes DermSCORE (an AI analytic that monitors acne lesions, comedones, or hyperpigmentation), allows consumers to register their DECODE DNA kits, and schedules consultations with genetic counselors.
  • Codex Labs can then continue working with the consumer to create a personalized regimen to address the skin condition.
  • We believe that data-driven, at-home dermatology represents the future of accessible care to those with skin conditions,” added Dr. Paldus.

The 6 Peptide Skin Booster Serum: A Dermatologist Led Sensation

Retrieved on: 
Friday, December 15, 2023
Peptide, Hyperpigmentation, Absorption, Social media, Skin, Nicotinamide, Vitamin C, Cosmetics, Vaccine

LOS ANGELES, Dec. 15, 2023 /PRNewswire/ -- COSRX, a dermatologist favorite skincare brand, has taken social media by storm thanks to its revolutionary The 6 Peptide Skin Booster Serum .

Key Points: 
  • LOS ANGELES, Dec. 15, 2023 /PRNewswire/ -- COSRX, a dermatologist favorite skincare brand, has taken social media by storm thanks to its revolutionary The 6 Peptide Skin Booster Serum .
  • And COSRX's The 6 Peptide Skin Booster Serum has done exactly that featuring not one but six peptides & six synergistic ingredients which include powerhouse ingredient, Copper Tripeptide.
  • He then goes on to introduce COSRX's The 6 Peptide Skin Booster Serum explaining that its lightweight consistency makes it perfect for the job.
  • Dermatologist approved, The 6 Peptide Skin Booster Serum ticks all the boxes.

Peace Out Skincare Expands Patented Acne Dot Line with Breakthrough Innovation

Retrieved on: 
Wednesday, December 13, 2023
Dark, Blemish, Absorption, Salicylic acid, Gen, Gland, Life, Head, Hyperpigmentation, Generation Alpha, LOS, Inflammation, Pimple, Generation Z, Skin, Cosmetics, Sephora, Acne

LOS ANGELES, Dec. 13, 2023 /PRNewswire/ -- Peace Out Skincare, the creators of the viral pimple patch movement, has once again revolutionized the approach to pimple care with the addition of their new Early Stage Acne Dot to its portfolio. This one-step targeted treatment is uniquely suited to attack blemishes residing below-the-surface and help minimize pimples before they come to a head.

Key Points: 
  • With over 75 millions Dots sold to date, Peace Out Skincare has captured an oversaturated market with their unparalleled offering of being the only brand with a patented, clean, and over-the-counter medicated pimple patch.
  • As The Experts in Acne Prone Skin, Peace Out Skincare is uniquely suited to cater to the needs of the growing Gen Z and Gen Alpha consumers by providing simple solutions to their chief skincare concern.
  • "At Peace Out Skincare our mission is to create an all-encompassing collection of innovative, first-to-market, targeted products and routines for your skin's lifetime journey.
  • The Early Stage Acne Dot is Peace Out Skincare's latest innovation in their pursuit of fun, easy-to-use and simple skincare solutions that leave you feeling confident to live-life unfiltered.